यूरोपीय संघ -
बुल्गारियाई -
EMA (European Medicines Agency)
rybrevant
janssen-cilag international n.v. - amivantamab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
यूरोपीय संघ -
बुल्गारियाई -
EMA (European Medicines Agency)
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - Хипофизни и хипоталамични хормони и аналози - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
यूरोपीय संघ -
बुल्गारियाई -
EMA (European Medicines Agency)
aqumeldi
proveca pharma limited - enalapril (maleate) - Сърдечна недостатъчност - Агенти, действащи върху системата ренин-ангиотензин - treatment of heart failure.